O	0	1	[	[	(	O
O	1	11	Expression	Expression	NN	B-NP
O	12	15	and	and	CC	O
O	16	24	mutation	mutation	NN	B-NP
O	25	27	of	of	IN	B-PP
O	28	29	c	c	NN	B-NP
O	29	30	-	-	HYPH	I-NP
O	30	33	kit	kit	NN	I-NP
O	34	38	gene	gene	NN	I-NP
O	39	41	in	in	IN	B-PP
B-Cancer	42	58	gastrointestinal	gastrointestinal	JJ	B-NP
I-Cancer	59	66	stromal	stromal	JJ	I-NP
I-Cancer	67	72	tumor	tumor	NN	I-NP
O	72	73	]	]	)	O
O	73	74	.	.	.	O

O	76	85	OBJECTIVE	OBJECTIVE	NN	B-NP
O	85	86	:	:	:	O
O	87	89	To	To	TO	B-VP
O	90	101	investigate	investigate	VB	I-VP
O	102	105	the	the	DT	B-NP
O	106	112	effect	effect	NN	I-NP
O	113	115	of	of	IN	B-PP
O	116	119	the	the	DT	B-NP
O	120	130	expression	expression	NN	I-NP
O	131	134	and	and	CC	I-NP
O	135	143	mutation	mutation	NN	I-NP
O	144	146	of	of	IN	B-PP
O	147	148	c	c	NN	B-NP
O	148	149	-	-	HYPH	I-NP
O	149	152	kit	kit	NN	I-NP
O	153	157	gene	gene	NN	I-NP
O	158	161	and	and	CC	O
O	162	165	its	its	PRP$	B-NP
O	166	178	relationship	relationship	NN	I-NP
O	179	183	with	with	IN	B-PP
O	184	192	clinical	clinical	JJ	B-NP
O	193	202	pathology	pathology	NN	I-NP
O	203	206	and	and	CC	I-NP
O	207	216	prognosis	prognosis	NN	I-NP
O	217	219	of	of	IN	B-PP
B-Cancer	220	236	gastrointestinal	gastrointestinal	JJ	B-NP
I-Cancer	237	244	stromal	stromal	JJ	I-NP
I-Cancer	245	250	tumor	tumor	NN	I-NP
O	251	252	(	(	(	O
B-Cancer	252	256	GIST	GIST	NN	B-NP
O	256	257	)	)	)	O
O	257	258	.	.	.	O

O	259	266	METHODS	METHODS	NNS	B-NP
O	266	267	:	:	:	O
O	268	287	Immunohistochemical	Immunohistochemical	JJ	B-NP
O	288	291	and	and	CC	I-NP
O	292	295	PCR	PCR	NN	I-NP
O	295	296	-	-	HYPH	B-NP
O	296	300	SSCP	SSCP	NN	I-NP
O	301	311	techniques	technique	NNS	I-NP
O	312	316	were	be	VBD	B-VP
O	317	321	used	use	VBN	I-VP
O	322	324	to	to	TO	B-VP
O	325	331	detect	detect	VB	I-VP
O	332	333	c	c	NN	B-NP
O	333	334	-	-	HYPH	I-NP
O	334	337	kit	kit	NN	I-NP
O	338	345	protein	protein	NN	I-NP
O	346	356	expression	expression	NN	I-NP
O	357	360	and	and	CC	O
O	361	362	c	c	NN	B-NP
O	362	363	-	-	HYPH	I-NP
O	363	366	kit	kit	NN	I-NP
O	367	371	gene	gene	NN	I-NP
O	372	376	exon	exon	NN	I-NP
O	377	379	11	11	CD	B-NP
O	380	388	mutation	mutation	NN	I-NP
O	389	391	in	in	IN	B-PP
O	392	394	82	82	CD	B-NP
O	395	403	patients	patient	NNS	I-NP
O	404	408	with	with	IN	B-PP
B-Cancer	409	413	GIST	GIST	NN	B-NP
O	413	414	.	.	.	O

O	415	422	RESULTS	RESULTS	NNS	B-NP
O	422	423	:	:	:	O
O	424	427	The	The	DT	B-NP
O	428	436	positive	positive	JJ	I-NP
O	437	438	c	c	NN	I-NP
O	438	439	-	-	HYPH	B-NP
O	439	442	kit	kit	NN	I-NP
O	443	450	protein	protein	NN	I-NP
O	451	461	expression	expression	NN	I-NP
O	462	465	and	and	CC	O
O	466	467	c	c	NN	B-NP
O	467	468	-	-	HYPH	I-NP
O	468	471	kit	kit	NN	I-NP
O	472	476	gene	gene	NN	I-NP
O	477	485	mutation	mutation	NN	I-NP
O	486	491	rates	rate	NNS	I-NP
O	492	496	were	be	VBD	B-VP
O	497	499	97	97	CD	B-NP
O	499	500	.	.	.	O
O	500	501	6	6	CD	B-NP
O	501	502	%	%	NN	I-NP
O	503	504	(	(	(	O
O	504	506	80	80	CD	B-NP
O	506	507	/	/	SYM	O
O	507	509	82	82	CD	B-NP
O	509	510	)	)	)	O
O	511	514	and	and	CC	O
O	515	517	41	41	CD	B-NP
O	517	518	.	.	.	O
O	518	519	5	5	CD	B-NP
O	519	520	%	%	NN	I-NP
O	521	522	(	(	(	O
O	522	524	34	34	CD	B-NP
O	524	525	/	/	SYM	O
O	525	527	82	82	CD	B-NP
O	527	528	)	)	)	O
O	528	529	.	.	.	O

O	530	541	Correlating	Correlate	VBG	B-VP
O	542	545	the	the	DT	B-NP
O	546	553	results	result	NNS	I-NP
O	554	556	of	of	IN	B-PP
O	557	562	these	these	DT	B-NP
O	563	566	two	two	CD	I-NP
O	567	574	methods	method	NNS	I-NP
O	575	578	and	and	CC	O
O	579	598	clinicopathological	clinicopathological	JJ	B-NP
O	599	606	factors	factor	NNS	I-NP
O	606	607	,	,	,	O
O	608	611	the	the	DT	B-NP
O	612	613	c	c	NN	I-NP
O	613	614	-	-	HYPH	B-NP
O	614	617	kit	kit	NN	I-NP
O	618	628	expression	expression	NN	I-NP
O	629	632	and	and	CC	O
O	633	634	c	c	NN	B-NP
O	634	635	-	-	HYPH	I-NP
O	635	638	kit	kit	NN	I-NP
O	639	643	gene	gene	NN	I-NP
O	644	652	mutation	mutation	NN	I-NP
O	653	658	rates	rate	NNS	I-NP
O	659	663	were	be	VBD	B-VP
O	664	666	95	95	CD	B-NP
O	666	667	.	.	.	O
O	667	668	0	0	CD	B-NP
O	668	669	%	%	NN	I-NP
O	670	671	(	(	(	O
O	671	673	19	19	CD	B-NP
O	673	674	/	/	SYM	I-NP
O	674	676	20	20	CD	I-NP
O	676	677	)	)	)	O
O	678	681	and	and	CC	O
O	682	683	0	0	CD	B-NP
O	684	686	in	in	IN	B-PP
B-Cancer	687	693	benign	benign	JJ	B-NP
I-Cancer	694	698	GIST	GIST	NN	I-NP
O	698	699	,	,	,	O
O	700	703	and	and	CC	O
O	704	708	were	be	VBD	B-VP
O	709	711	98	98	CD	B-NP
O	711	712	.	.	.	O
O	712	713	4	4	CD	B-NP
O	713	714	%	%	NN	I-NP
O	715	716	(	(	(	O
O	716	718	61	61	CD	B-NP
O	718	719	/	/	SYM	O
O	719	721	62	62	CD	B-NP
O	721	722	)	)	)	O
O	722	723	,	,	,	O
O	724	726	54	54	CD	B-NP
O	726	727	.	.	.	O
O	727	728	8	8	CD	B-NP
O	728	729	%	%	NN	I-NP
O	730	731	(	(	(	O
O	731	733	34	34	CD	B-NP
O	733	734	/	/	SYM	O
O	734	736	62	62	CD	B-NP
O	736	737	)	)	)	O
O	738	740	in	in	IN	B-PP
B-Cancer	741	750	malignant	malignant	JJ	B-NP
I-Cancer	751	755	GIST	GIST	NN	I-NP
O	755	756	.	.	.	O

O	757	765	Mutation	Mutation	NN	B-NP
O	766	774	positive	positive	JJ	I-NP
B-Cancer	775	779	GIST	GIST	NN	I-NP
O	780	786	showed	show	VBD	B-VP
O	787	793	higher	high	JJR	B-NP
O	794	803	frequency	frequency	NN	I-NP
O	804	806	of	of	IN	B-PP
O	807	815	adjacent	adjacent	JJ	B-NP
B-Tissue	816	822	tissue	tissue	NN	I-NP
O	823	831	invasion	invasion	NN	I-NP
O	831	832	,	,	,	O
O	833	843	metastasis	metastasis	NN	B-NP
O	844	847	and	and	CC	I-NP
O	848	858	recurrence	recurrence	NN	I-NP
O	859	861	as	as	IN	B-PP
O	862	870	compared	compare	VBN	B-PP
O	871	875	with	with	IN	B-PP
O	876	884	mutation	mutation	NN	B-NP
O	885	893	negative	negative	JJ	I-NP
O	894	898	ones	one	NNS	I-NP
O	898	899	.	.	.	O

O	900	910	CONCLUSION	CONCLUSION	NN	B-NP
O	910	911	:	:	:	O
O	912	913	c	c	NN	B-NP
O	913	914	-	-	HYPH	I-NP
O	914	917	kit	kit	NN	I-NP
O	918	925	protein	protein	NN	I-NP
O	926	928	is	be	VBZ	B-VP
O	929	931	an	an	DT	B-NP
O	932	941	important	important	JJ	I-NP
O	942	952	diagnostic	diagnostic	JJ	I-NP
O	953	959	marker	marker	NN	I-NP
O	960	962	of	of	IN	B-PP
B-Cancer	963	979	gastrointestinal	gastrointestinal	JJ	B-NP
I-Cancer	980	987	stromal	stromal	JJ	I-NP
I-Cancer	988	993	tumor	tumor	NN	I-NP
O	993	994	.	.	.	O

O	995	996	c	c	SYM	O
O	996	997	-	-	:	O
O	997	1000	kit	kit	NN	B-NP
O	1001	1005	gene	gene	NN	I-NP
O	1006	1014	mutation	mutation	NN	I-NP
O	1015	1018	may	may	MD	B-VP
O	1019	1023	play	play	VB	I-VP
O	1024	1025	a	a	DT	B-NP
O	1026	1037	significant	significant	JJ	I-NP
O	1038	1042	role	role	NN	I-NP
O	1043	1045	in	in	IN	B-PP
O	1046	1049	the	the	DT	B-NP
O	1050	1062	pathogenesis	pathogenesis	NN	I-NP
O	1063	1065	of	of	IN	B-PP
B-Cancer	1066	1070	GIST	GIST	NN	B-NP
O	1071	1074	and	and	CC	O
O	1075	1079	also	also	RB	B-VP
O	1080	1083	may	may	MD	I-VP
O	1084	1086	be	be	VB	I-VP
O	1087	1088	a	a	DT	B-NP
O	1089	1099	prognostic	prognostic	JJ	I-NP
O	1100	1106	marker	marker	NN	I-NP
O	1106	1107	.	.	.	O

